Scotiabank Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Perform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and raises the price target from $85 to $86.
August 06, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scotiabank analyst George Farmer maintains a Sector Perform rating on Biomarin Pharmaceutical and raises the price target from $85 to $86.
The raised price target from $85 to $86 by Scotiabank indicates a slightly more positive outlook on Biomarin Pharmaceutical. This could lead to a minor positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100